top of page

Global new Drug R&D express: Janssen Pharma's guselkumab,AstraZeneca's ravulizumab,SMT112

1 First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

Janssen Pharma announced the results from the Phase 3 QUASAR Induction Study (NCT04033445) of guselkumab for the treatment of adults with moderately to severely active ulcerative colitis. The data showed statistically significant and clinically meaningful remission (22.6% vs. 7.9%, p <0.001) of guselkumab compared to placebo at Week 12, meeting its primary endpoint. Besides, a greater proportion of guselkumab group at Week 12 achieved with clinical response (61.5% vs. 27.9%, p<0.001), endoscopic improvement (26.8% vs. 11.1%, p<0.001) and histo-endoscopic mucosal improvement (23.5% vs. 7.5%, p<0.001). The TEAEs in guselkumab group were generally comparable to placebo group.

2 Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

AstraZeneca announced the European Union approved of Ultomiris (ravulizumab) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). The approval was based on the phase 3 CHAMPION-NMOSD (NCT04201262) Study, which showed Ultomiris had a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p<0.0001) and continuing through a median duration of 90 weeks.

3 Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized, double-blinded study, enrolled patients from the US, Canada, Europe, and China. The study will evaluate the efficacy and safety of ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd-generation EGFR TKI such as osimertinib.

!!!Tips for getting the latest and accurate information for your interesting information:

By clicking on the bold and underlined keywords within the article, like the pharmaceutical company's name or the drug's name, you will be directed to the most recent research and development updates of the company. These updates encompass essential details such as the layout of their research pipeline, technological platforms, target priorities, investment initiatives, patent statuses, clinical trial progress, and comprehensive insights into the drug's latest advancements. This includes its mechanism of action, target treatment areas, and current development status.



Recent Posts

See All


bottom of page